Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease

Summary Background Vedolizumab specifically recognises the α4β7 integrin and selectively blocks gut lymphocyte trafficking: potentially, it offers gut‐specific immunosuppression. Aim To review the safety of vedolizumab and summarise post‐marketing data to assess if any safety concerns that differ from registration trials have emerged. Method A systematic bibliographic search identified six registration trials and nine cohort studies. Results...